James R Perry
Overview
Explore the profile of James R Perry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
2954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malmstrom A, Oppong F, O Callaghan C, Wick W, Laperriere N, Gorlia T, et al.
Neurooncol Adv
. 2025 Jan;
6(1):vdae211.
PMID: 39759261
Background: The majority of patients diagnosed with glioblastoma are >60 years. Three randomized trials addressed the roles of radiotherapy (RT) and temozolomide (TMZ) for elderly patients. NORDIC and NOA-08 compared...
2.
Hegi M, Oppong F, Perry J, Wick W, Henriksson R, Laperriere N, et al.
Neuro Oncol
. 2024 Jun;
26(10):1867-1875.
PMID: 38912869
Background: The treatment of elderly/ frail patients with glioblastoma is a balance between avoiding undue toxicity, while not withholding effective treatment. It remains debated, whether these patients should receive combined...
3.
Roberto K, Perry J
Neurooncol Pract
. 2024 Mar;
11(2):113-114.
PMID: 38496918
No abstract available.
4.
Pant S, Wainberg Z, Weekes C, Furqan M, Kasi P, Devoe C, et al.
Nat Med
. 2024 Jan;
30(2):531-542.
PMID: 38195752
Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node...
5.
Mellinghoff I, van den Bent M, Blumenthal D, Touat M, Peters K, Clarke J, et al.
N Engl J Med
. 2023 Jun;
389(7):589-601.
PMID: 37272516
Background: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed...
6.
Melhem J, Tahir A, Calabrese E, Granovskaya I, Atenafu E, Sahgal A, et al.
J Neurooncol
. 2023 Feb;
161(3):633-641.
PMID: 36749445
Background: Bevacizumab (BEV), at a standard dose of 10 mg/kg every 2 weeks is associated with prolonged progression-free survival (PFS) but no improvement in overall survival (OS) in recurrent glioblastoma...
7.
Melhem J, Detsky J, Lim-Fat M, Perry J
Neurotherapeutics
. 2022 May;
19(6):1705-1723.
PMID: 35641844
Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs...
8.
Ironside S, Sahgal A, Detsky J, Das S, Perry J
Ann Palliat Med
. 2020 Nov;
10(1):899-908.
PMID: 33222472
Glioblastoma in the elderly (>65 years of age) is associated with shorter overall survival (OS) than in younger patients. Best practice recommendations for elderly patients, especially those with borderline or...
9.
Climans S, Brandes A, Cairncross J, Ding K, Fay M, Laperriere N, et al.
J Neurooncol
. 2020 Jul;
149(1):65-71.
PMID: 32632894
Introduction: Tumor-related epilepsy may respond to chemotherapy. In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone....
10.